U.S. markets close in 2 hours 55 minutes

CB Scientific, Inc. (CBSC)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.39000.0000 (0.00%)
As of 2:01PM EST. Market open.
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.3900
Open1.3900
BidN/A x N/A
AskN/A x N/A
Day's Range1.3900 - 1.3900
52 Week Range0.0300 - 2.5000
Volume25
Avg. Volume1,157
Market Cap81.445M
Beta (5Y Monthly)-0.55
PE Ratio (TTM)N/A
EPS (TTM)-0.0110
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • CB Scientific, Inc. (CBSC) Announces Definitive Agreement to Acquire Commercial Ambulatory ECG Device Manufacturer Datrix, LLC
    GlobeNewswire

    CB Scientific, Inc. (CBSC) Announces Definitive Agreement to Acquire Commercial Ambulatory ECG Device Manufacturer Datrix, LLC

    Acquisition will expand Ambulatory Remote Cardiac ECG Monitoring product technology offering and outreach into US and international marketsESCONDIDO, Calif., Nov. 12, 2020 (GLOBE NEWSWIRE) -- via InvestorWire - CB Scientific. Inc. (OTC:CBSC) ("CBSC" or the "Company"), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, is pleased to announce a definitive purchase agreement to acquire Datrix, LLC (Datrix), a global ambulatory device manufacturer based in Escondido, California. Datrix brings to CBSC a diversely experienced team of highly qualified individuals with extensive knowledge of design and engineering related to medical devices utilized in this ever-expanding market. This acquisition further strengthens CBSC’s digital offering with the addition of an existing commercially available product line, which includes wireless mobile cardiac telemetry, cardiac event, extended and standard holter monitoring through the Datrix Sirona and VX3 devices.         Under the terms of the acquisition agreement, Datrix will continue to operate as an OEM manufacturer to its existing customer base and also become the exclusive manufacturer for the next generation of CBSC’s proprietary FDA- and CE-cleared ECG my-Cam Cardiac Event Monitor, including the interactive cloud-based My-Cardia acquisition software and the associated smartphone apps. This acquisition also provides CBSC and its subsidiary My-Cardia (USA) Inc. the opportunity to expand their product offerings quickly with the addition, integration and implementation of Datrix’s wireless Sirona and VX3 devices. The addition of these new products to CBSC’s existing portfolio will now give the Company’s customers several new alternative monitoring/testing choices, which will further help improve earlier remote detection and diagnosis of problematic cardiac rhythms in patients.  Jon Barron, president and founder of Datrix, LLC, said, "We are enthusiastic about our exciting new partnership with CBSC. They provide a great new platform for us to extend the outreach of our current products, improve and enhance their existing offerings, and expand the design and development of newer device technologies, leading to new avenues for improving the detection of cardiac heart rhythm abnormalities remotely.""We are extremely excited about our acquisition of Datrix, LLC and how it enhances and strengthens the growth trajectory of our business,” said Charles Martin, CBSC CEO. “The acquisition, combined with other expansion efforts already underway, will position CBSC to play a significant role in delivering innovative diagnostic devices and testing into this ever-expanding market, further helping our company to establish a solid footprint in the worldwide remote cardiac ambulatory noninvasive ECG monitoring market." The acquisition is expected to close during Q4 of fiscal year 2020, subject to customary closing conditions.  Financial terms of the agreement are not being disclosed.As new developments occur, CB Scientific plans to make further announcements through press releases and regulatory filings to keep its shareholders, industry participants and the public markets informed. About Datrix, LLC:Datrix, LLC is a leading global manufacturer and provider of ambulatory ECG devices, established in 1988.  For over 30 years, medical companies, distributors and dealers have partnered with Datrix to design and develop dependable products with the latest technologies and advancements that meet the highest industry standard. Datrix’s approach to quality exceeds today’s requirements through the implementation of lean manufacturing practices. Their Quality Management System is certified to international standards of ISO 13485 and is in compliance with the Quality Systems Regulations of the FDA, with proprietary devices also bearing CE marking for conformity for marketing in the European Union. The manufacturing facility is registered with the FDA. For more information, please visit: www.datrixmed.com.CB Scientific Inc. Company Contact Information: 340 State Place Escondido, CA 92029 Telephone number: (888) 225-0870Emails: General inquires: info@cbscientificinc.com Investor Inquiries: investor@cbscientificinc.comCompany Website and Social Media Outlets: CB Scientific website, Twitter, Facebook, Instagram and LinkedInThis information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995. These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties. Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications. When used in this press release, the words “plan,” “expect,” “believe” and similar expressions generally identify forward-looking statements. These statements reflect our current expectations. They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets. This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934. Statements contained in this release that are not historical facts may be deemed to be forward-looking statements.  Investors are cautioned that forward-looking statements are inherently uncertain. Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.Wire Service Contact InvestorWire (IW) Los Angeles, California www.InvestorWire.com 212.418.1217 Office Editor@InvestorWire.com

  • GlobeNewswire

    CB Scientific, Inc. (CBSC) Announces the Launch of My-Cardia ECG Products and Services in Thailand

    Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. to begin exclusive distribution of CB Scientific’s FDA & CE-cleared EKG products to an expansive private and government hospital networkESCONDIDO, Calif., Oct. 08, 2020 (GLOBE NEWSWIRE) -- via Network Wire -- CB Scientific. Inc. (OTC:CBSC) ("CBSC" or the "Company"), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, announces today the targeted start of cardiac lab services operations in the country of Thailand through the Company’s exclusive authorized distributor, Mango Wellness Co., Ltd. (MWC) and My Cardia Thailand Co., Ltd. (MCT), beginning Oct. 29, 2020. Under terms of the distribution agreement, Mango Wellness Co., Ltd. and My Cardia Thailand Co., Ltd. will be the exclusive distributor for CBSC’s proprietary FDA and CE-cleared EKG my-Cam Cardiac Event Monitor, the interactive cloud-based My-Cardia acquisition software, and the associated smartphone apps for both iOS and Android platforms in Thailand. The My-Cardia product line is designed specifically for the Remote Cardiac Ambulatory ECG market to help in the detection of abnormal heart rhythms while providing improved compliance for the patient, as well as more timely, convenient and accurate information for the physician."Mango Wellness and My Cardia Thailand is committed to providing and delivering the best wellness and healthcare ECG services to more than 1,300 private and government hospitals in Thailand to assist our healthcare providers and physicians in early detection and diagnosis of a patient’s abnormal cardiac rhythm," said Joe Chan, executive director for Mango Wellness and My Cardia Thailand. "With a total population of 69 million people in Thailand, where cardiovascular disease has increased steadily over the past decade and is now the major leading cause of death in our country, this clearly indicates the critical need for innovative diagnostic products and services like these in Thailand. Offering the My-Cardia line of Ambulatory ECG devices and software will provide an alternative monitoring choice for our customers to improve the earlier detection of problematic cardiac rhythms which will help to improve patients' lives."Charles Martin, CBSC CEO, added, "Mango Wellness and My Cardia Thailand is a great partner for the distribution of our products and services in Thailand. They have the reputation and clinical experience there to help make our My-Cardia products a market leader in their country. This launch, together with the upcoming targeted distribution start-ups in Malaysia and Singapore in the coming months and our continued work towards NMPA (National Medical Products Administration, formerly CFDA) certification in China, will go a long way towards helping our company establish a solid footprint in the Ambulatory noninvasive ECG monitoring market in Asia."The distribution agreement may be expanded with additional products and territories in the future. Financial terms of the agreement were not disclosed.CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.CB Scientific Inc.Contact Information: 340 State Place Escondido, CA 92029 Telephone number: (888) 225-0870Emails: General inquires: info@cbscientificinc.com Investor Inquiries: investor@cbscientificinc.comCompany Website and Social Media Outlets: CB Scientific website, Twitter, Facebook, Instagram and LinkedInMango Wellness Co., Ltd./My Cardia Thailand Co., Ltd. Contact Information: Mango Wellness Co., Ltd. Glas Haus Building, Level P, Unit PO1 1 Sukhumvit 25, North Klongtoey Wattana, Bangkok, Thailand 10110My Cardia Thailand Co., Ltd. 190 Sutthisan Road, Intersection 1 Ratchadaphisek, Dindaeng Bangkok, Thailand 10400Telephone number: +66 (0) 21015576 – Mango Wellness +66 (0) 971566481 – My Cardia ThailandEmails: General inquires: info@mangowellnessthailand.com                                    info@mycardiathailand.comCompany Website and Social Media Outlets: Mango Wellness Thailand website, Twitter, Facebook, Instagram and YouTube My-Cardia Thailand website, Facebook and YouTubeThis information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995.  These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties.  Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications.  When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements.  These statements reflect our current expectations.  They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.  This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934.  Statements contained in this release that are not historical facts may be deemed to be forward-looking statements.  Investors are cautioned that forward-looking statements are inherently uncertain.  Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.Wire Service Contact:  NetworkWire (NW)  New York, New York www.NetworkWire.com 212.418.1217 Office Editor@NetworkWire.com

  • GlobeNewswire

    CB Scientific, Inc. (CBSC) Announces Completion of Asset Purchase Agreement and Commencement of Its ECG Monitoring Business

    An experienced executive management team is leading the way in the FDA and CE-cleared cardiac monitoring products and services arena, using smart phones and cloud-based software technologyESCONDIDO, Calif., Sept. 22, 2020 (GLOBE NEWSWIRE) -- via NetworkWire -- CB Scientific, Inc. (OTC: CBSC) (“CBSC” or the “Company”), a provider of innovative products and services for the ambulatory noninvasive cardiac monitoring space, announces recent disclosures regarding its acquisition of the operating business assets of Prevent Health Care International Corp. (PHCIC) and the disposition of CBSC’s former business assets related to cannabis testing products and services.CB Scientific, Inc. announces that it has concluded the acquisition of business assets, pursuant to an agreement with certain secured investors and controlling shareholders of Prevent Health Care International Corp., a private British Columbia, Canada, corporation. The agreement enabled CBSC to acquire all of the ownership interests in all of the assets of PHCIC, including its medical technology products developed to date; its intellectual property; manufacturing know-how; any and all patents; and all related information and knowledge necessary to promote, market and sell its product line in all global markets, excluding Australia.The acquired products and services are available in the U.S. and through PHCIC’s international subsidiaries using proprietary FDA and CE-cleared EKG devices, interactive cloud-based acquisition software, and smartphone apps for both iOS and Android platforms. The combination of devices and software provides improved compliance for patients at risk of abnormal heart rhythms, as well as more accurate information for physicians. The disclosures also provide information on changes in the Company’s key executive management as well as details of these individuals’ previous experience. CBSC has committed to provide updates and further details on the progress of the business as key milestones are met.In connection with this, CBSC has acquired ownership and taken control of the subsidiaries of PHCIC, including My-Cardia USA Inc. and related businesses. CBSC has assembled a core management team including key personnel from PHCIC, as well as new additions to the team, to continue the previous activities of PHCIC and its subsidiaries. This includes ongoing sales and support for physicians and patients, in addition to relationships with contracted suppliers, subcontractors, distribution partners and affiliates. Going forward, CBSC will be involved in the development, sale and service of innovative arrhythmia diagnostics and heart-monitoring solutions, including intellectual property and related products.In connection with the asset purchase agreement, CBSC has divested its previous cannabis-related testing products and services business in order to focus on the medical monitoring business going forward. Company operations and headquarters will initially be located in Escondido, California, pending further plans and possible developments. CBSC is developing and refining its corporate communications capabilities, including its website and media relations, in order to better communicate the business objectives of the Company and to provide regular information updates.Charles Martin, CBSC CEO, stated, “I am very optimistic about CB Scientific’s future prospects, as a result of becoming a public company, and the opportunities available for our proprietary cardiac products and cloud-based applications. The market for heart monitoring has grown substantially over the past decade, and our international target markets have a huge need for our products and services. I expect sales to grow rapidly.”CBSC is now fully committed to the further development and expansion of its cardiac arrhythmia diagnostic heart-monitoring technology, called the myCam, through its new subsidiary My-Cardia (USA) Inc., whose primary focus is the Remote Cardiac Ambulatory ECG market, both domestically and internationally. Related to this will be ongoing efforts to expand My-Cardia's product and service capabilities through expansion of business relationships and possible acquisitions.CB Scientific plans to make further announcements to keep its shareholders, industry participants and the public markets informed through press releases and regulatory filings as new developments occur.Company Contact Information: 340 State Place Escondido, CA 92029Telephone number: (888) 225-0870Emails: General inquires: info@cbscientificinc.com Investor Inquiries: investor@cbscientificinc.comCompany Website and Social Media Outlets: CB Scientific website, Twitter, Facebook, Instagram and LinkedIn   This information disclosure may contain forward-looking statements covered within the meaning of the Private Securities Litigation Act of 1995.  These forward-looking statements relate to, among other things, plans and timing for the introduction or enhancement of our services and products, statements about future market conditions, supply and demand conditions, and other expectations, intentions and plans contained in this press release that are not historical fact and involve risks and uncertainties.  Our expectations regarding future revenues depend upon our ability to develop and supply products and services that we may not produce today and that meet defined specifications.  When used in this press release, the words “plan,” “expect,” “believe,” and similar expressions generally identify forward-looking statements.  These statements reflect our current expectations.  They are subject to a number of risks and uncertainties, including, but not limited to, changes in technology and changes in pervasive markets.  This release includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 27E of the Securities Act of 1934.  Statements contained in this release that are not historical facts may be deemed to be forward-looking statements.  Investors are cautioned that forward-looking statements are inherently uncertain.  Actual performance and results may differ materially from that projected or suggested herein due to certain risks and uncertainties including, without limitation, ability to obtain financing and regulatory and shareholder approval for anticipated actions.NOT FOR RELEASE IN CANADAWire Service Contact: NetworkWire (NW) New York, New York www.NetworkWire.com 212.418.1217 Office Editor@NetworkWire.com